Clinical Trials on Hormone Receptor Positive (HR ), HER2-negative Breast Cancer

Total 1048 results

QuantumLeap Healthcare Collaborative

Recruiting

PRE-I-SPY Phase I/Ib Oncology Platform Program (PRE-I-SPY-PI)

Solid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditions

United States
Laura M. Spring, MD
Merck Sharp & Dohme LLC; Translational Breast Cancer Research Consortium; Breast...

Recruiting

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Triple Negative Breast Cancer | Hormone Receptor Positive (HR+), HER2-negative Breast Cancer | Biopsy-proven, Positive Lymph Node(s)

United States
QuantumLeap Healthcare Collaborative
Byondis B.V.

Withdrawn

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Ovarian Cancer | Metastatic Cancer | Metastatic Breast Cancer | Bladder Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Gastroesophageal Adenocarcinoma | Ovarian Carcinoma | HER2-positive Gastric Cancer | Metastatic Gastrointestinal Carcinoid Tumor | HER2-positive Metastatic Breast... and other conditions

United States
Fudan University

Recruiting

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (FASCINATE-N)

Breast Cancer | Breast Neoplasm | Breast Tumors | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer | Triple-Negative Breast Cancer (TNBC)

China
National Cancer Institute (NCI)

Terminated

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive and other conditions

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Genentech, Inc.; Translational Breast Cancer... and other collaborators

Terminated

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Stage IV Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)

Completed

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IIIC Breast Cancer AJCC v6 | Stage IV Breast Cancer AJCC v6 and v7

United States, Puerto Rico
BeiGene

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Advanced Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer | Hormone-receptor-positive...

Australia, United States
Adrienne G. Waks
Eli Lilly and Company; Verastem, Inc.

Recruiting

VS-6766+Abema+Fulv in Met HR+/HER- BC

Breast Cancer | Hormone Receptor-positive Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer

United States
National Cancer Institute (NCI)

Terminated

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive

United States
University of Washington
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...

United States
Daiichi Sankyo

Completed

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

HER2-negative Breast Cancer | HER2-low Breast Cancer | Hormone-receptor-positive Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Florida Breast Cancer Foundation

Recruiting

Study of Screening Brain MRIs in Stage IV Breast Cancer

Triple Negative Breast Cancer | HER2-positive Breast Cancer | Hormone Receptor-positive Breast Cancer

United States
QuantumLeap Healthcare Collaborative

Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)

Breast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer

United States
BeiGene

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Hormone Receptor Positive Malignant Neoplasm of Breast | HER2-negative Breast Cancer | Hormone-receptor-positive Breast Cancer

China
Baylor Breast Care Center

Recruiting

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer (RESPONSE)

Breast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer Invasive

United States
Ellipses Pharma

Recruiting

Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer

Metastatic Breast Cancer | Hormone Receptor-positive Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer

United States, Spain, United Kingdom
Laura Huppert, MD, BA
Ambrx, Inc.

Not yet recruiting

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Triple Negative Breast Cancer | Hormone Receptor Positive Breast Carcinoma | HER2 Low Breast Carcinoma | Hormone-receptor-positive Breast Cancer

United States
University of Nebraska
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone... and other conditions

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

HR-positive, HER2-negative Advanced Breast Cancer

China
Henan Cancer Hospital

Recruiting

Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

HR Positive HER2 Negative Advanced Breast Cancer

China
National Cancer Centre, Singapore
MSD Pharma (Singapore) Pte Ltd

Recruiting

Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole (LaPemERLA)

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

Singapore
Novartis Pharmaceuticals

Completed

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Japan, Hong Kong, Singapore
Dana-Farber Cancer Institute
Pfizer

Completed

Palbociclib With Everolimus + Exemestane In BC

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Hormone Receptor (HR)-Positive Breast Cancer

United States
Tianjin Medical University Cancer Institute and...

Recruiting

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

HR Positive HER2 Negative Advanced Breast Cancer

China
University of California, Irvine

Recruiting

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

Breast Cancer | Metastatic Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor-positive Breast Cancer

United States
Sun Pharma Advanced Research Company Limited

Terminated

A Study in Patients With Advanced Breast Cancer

Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor-positive Breast Cancer

United States, India
Institut fuer Frauengesundheit
Novartis Pharmaceuticals; AGO Breast Study Group e.V.

Recruiting

CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer (CLEAR-B)

Breast Cancer | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer

Germany
Olema Pharmaceuticals, Inc.

Active, not recruiting

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer

United States, Australia
Prof. Wolfgang Janni
Eli Lilly and Company

Recruiting

Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management (MINERVA)

Hormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast Cancer

Germany, Switzerland
CytomX Therapeutics

Completed

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Neoplasms | Breast Cancer | Breast Neoplasms | Breast Neoplasms, Triple-Negative | Breast Neoplasms, Hormone Receptor Positive/HER2 Negative

United States, Spain, Korea, Republic of
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

HR-positive,HER2-negative in Advanced Breast Cancer

China
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Metastatic Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Androgen Receptor Positive

United States
SOLTI Breast Cancer Research Group

Recruiting

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer (SOLTI-2104)

Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Premenopausal Breast Cancer

Spain
Yongsheng Wang
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

Locally Advanced Breast Cancer | Hormone Receptor Positive，HER2-negative Breast Cancer

China
VelosBio Inc.

Completed

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)

Gastric Cancer | Pancreatic Cancer | NSCLC | Platinum-resistant Ovarian Cancer | Triple-negative Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Non-squamous Non-small-cell Lung Cancer | Estrogen-receptor-positive Breast Cancer | Progesterone-receptor-positive Breast Cancer | Estrogen-receptor-negative... and other conditions

United States, Canada
Clovis Oncology, Inc.

Terminated

A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Estrogen Receptor Positive | Triple Negative | HER2 | HER2 Positive | MBC | ER

United States
University of Washington
Breast Cancer Research Foundation

Not yet recruiting

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic HER2-Negative Breast Carcinoma | Metastatic Hormone Receptor-Positive Breast Carcinoma | Locally Advanced Unresectable HER2-Negative Breast Carcinoma | Locally Advanced Unresectable Hormone Receptor-Positive...

United States
Olema Pharmaceuticals, Inc.
Novartis

Recruiting

Phase 1b Combo w/ Ribociclib and Alpelisib

Advanced Breast Cancer | Metastatic Breast Cancer | HR-positive Breast Cancer | HER2-negative Breast Cancer

United States, Australia
Seagen Inc.

Completed

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Triple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast Neoplasms

United States
National Cancer Institute (NCI)

Terminated

RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer

China
Fudan University
Chongqing University Cancer Hospital; Sun Yat-sen University; Peking University... and other collaborators

Recruiting

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer | Breast Neoplasm | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor

China
Dana-Farber Cancer Institute
Conquer Cancer Foundation

Recruiting

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Inflammatory Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast

United States
Peking Union Medical College Hospital

Not yet recruiting

Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC (Pyrotinib)

Breast Diseases | Metastatic Breast Cancer | HER2-positive Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer Female | Hormone Receptor Positive Tumor
Ana C Garrido-Castro, MD
Merck Sharp & Dohme LLC; Gilead Sciences

Active, not recruiting

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Metastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | HR-Positive Breast Cancer

United States
Fuzhou General Hospital

Not yet recruiting

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Breast Diseases | Metastatic Breast Cancer | HER2-positive Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer Female | Hormone Receptor Positive Tumor

China
Virginia Commonwealth University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Active, not recruiting

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IIA Breast Cancer | Stage IIB Breast Cancer | HER2/Neu Negative | Progesterone Receptor Negative | Estrogen Receptor-positive Breast Cancer | Breast Adenocarcinoma | Progesterone Receptor Positive... and other conditions

United States
Novartis Pharmaceuticals

No longer available

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

Advanced Hormone Receptor Positive (HR+) Breast Cancer

Clinical Trials on Hormone Receptor Positive (HR ), HER2-negative Breast Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations